PacBio
PacBio's revenue rose 3.9% to $160 million in fiscal 2025. Its operating margin was −346.1%, down from −308.0% a year earlier. Free cash flow was −$114 million. The diluted share count rose 4.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What PacBio does
Pacific Biosciences, known as PacBio, makes machines that read DNA. Its HiFi long-read sequencing reads much longer stretches of DNA at a time than older methods, which helps researchers see complex parts of the genome. Its instruments are the Revio, Vega and Sequel systems, which read DNA on small chips called SMRT Cells. It sells the instruments, plus the SMRT Cells, other consumables and software they need.
Its customers include university and government research institutes, commercial testing and service labs, genome centers, public health labs, hospitals, contract research organizations, drug companies and agricultural companies. The uses range from human genetic disease and cancer to plant and animal science and infectious disease.
On January 30, 2026, PacBio sold assets for its short-read sequencing technology to Illumina, a competitor. Illumina paid $50.0 million in cash and took on certain liabilities, and PacBio kept a non-exclusive license to some of the technology. PacBio has lost money so far and is cutting costs. It says it is not cash flow positive and that it may not have enough cash to make its debt payments.
Its biggest risks, as it describes them
- Losses to date, with no assurance it will ever become profitable.
- Not being cash flow positive, and possibly lacking cash for debt payments and long-term plans.
- Cost-cutting that could disrupt its operations without delivering the expected savings.
- The sale of its short-read sequencing assets, which could hurt its business.
- Failing to develop, make and sell its current and new products, and leadership changes.
Income statement
PacBio lost money in fiscal 2025: a net loss of $546 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 1,044 | 772 | 631 | 390 | 280 |
| Debt incl. finance leases | 898 | 898 | 893 | 648 | 645 |
| Net debt (negative means net cash) | −147 | 126 | 261 | 258 | 366 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 1.1x | 1.6x | 1.3x | 1.3x | — |
| Interest coverage | −16.8x | −20.9x | −23.3x | −35.4x | −79.7x |
| Current ratio | 15.4x | 3.2x | 7.8x | 7.5x | 5.2x |
| Quick ratio | 15.0x | 3.0x | 7.2x | 6.6x | 4.5x |
Cash flow
Projections
Project PacBio's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What PacBio says to expect
- Full year 2026: revenue
PacBio now expects revenue for the full year 2026 to be in the range of $155 million to $160 million.
Insider trades
No officer, director or 10% owner of PacBio reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 2 of 9 | 3 of 9 |
| Rule of 40 | −77.4% | −161.0% | −67.3% |
| Altman Z'' | −1.59 | −5.15 | −13.42 |
| Accruals ratio | −2.7% | −6.9% | −42.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Fail | Pass |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 3 of 9 | 2 of 9 | 3 of 9 |
Compare
Put PacBio side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| PacBio | FY25 | 3.9% | −346.1% | −71.2% | −77.1% | — | 3 | |
| Ginkgo Bioworks | FY25 | −25.1% | −185.3% | −105.0% | — | — | — | Compare |
| Cryoport | FY25 | 12.4% | −20.9% | −14.2% | −23.4% | — | 4 | Compare |
| Maravai LifeSciences | FY25 | −28.3% | −115.9% | −38.1% | −32.0% | — | 2 | Compare |
| Cytek Biosciences | FY25 | 0.5% | −20.0% | −4.3% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 91 | 94 | 79 | 91 | 79 | 130 | 128 | 200 | 154 | 160 |
| Revenue growth | −2.2% | 3.0% | −15.9% | 15.6% | −13.2% | 65.4% | −1.7% | 56.3% | −23.2% | 3.9% |
| Gross profit | 44 | 35 | 25 | 35 | 33 | 59 | 49 | 53 | 37 | 46 |
| Research and development | 68 | 65 | 63 | 60 | 64 | 113 | 193 | 187 | 135 | 97 |
| Operating income | −71 | −90 | −101 | −100 | −104 | −210 | −307 | −334 | −474 | −554 |
| Net income | −74 | −92 | −103 | −84 | 29 | −181 | −314 | −307 | −310 | −546 |
| Diluted EPS (US$) | −0.83 | −0.87 | −0.76 | −0.55 | 0.17 | −0.89 | −1.40 | −1.21 | −1.59 | −1.82 |
| Diluted shares (millions) | 89 | 106 | 135 | 152 | 175 | 204 | 224 | 254 | 288 | 300 |
| Cash flow | ||||||||||
| Cash from operations | −68 | −68 | −66 | −78 | 20 | −111 | −263 | −259 | −206 | −111 |
| Capital expenditure | 8 | 10 | 2 | 3 | 1 | 6 | 17 | 9 | 6 | 3 |
| Free cash flow | −76 | −78 | −68 | −81 | 18 | −117 | −280 | −268 | −212 | −114 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 20 | 20 | 23 | 16 | 18 | 73 | 79 | 72 | 71 | 42 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 72 | 63 | 102 | 49 | 319 | 1,044 | 772 | 631 | 390 | 280 |
| Debt incl. finance leases | 16 | 14 | 15 | 16 | — | 898 | 898 | 893 | 648 | 645 |
| Total assets | 138 | 144 | 170 | 148 | 414 | 2,007 | 1,767 | 1,746 | 1,260 | 784 |
| Total liabilities | 53 | 58 | 56 | 93 | 78 | 1,216 | 1,204 | 1,045 | 754 | 779 |
| Shareholders' equity | 85 | 86 | 114 | 55 | 336 | 791 | 563 | 701 | 507 | 5 |
| Margins and ratios | ||||||||||
| Gross margin | 48.7% | 37.1% | 31.9% | 38.0% | 41.3% | 45.1% | 38.2% | 26.3% | 24.2% | 28.6% |
| Operating margin | −78.5% | −96.1% | −128.4% | −110.6% | −132.3% | −161.2% | −239.4% | −166.8% | −308.0% | −346.1% |
| Net margin | −82.0% | −98.6% | −130.4% | −92.6% | 37.3% | −138.8% | −244.9% | −153.0% | −201.2% | −341.5% |
| Free cash flow margin | −83.9% | −83.4% | −86.8% | −89.3% | 23.4% | −89.7% | −218.2% | −133.7% | −137.8% | −71.2% |
| Rule of 40 (growth + FCF margin) | −86.2% | −80.4% | −102.7% | −73.7% | 10.2% | −24.3% | −219.9% | −77.4% | −161.0% | −67.3% |
| Return on capital | −321.7% | −216.2% | −252.4% | −330.6% | — | — | −36.4% | −32.0% | −43.4% | −77.1% |
| Return on equity | −94.0% | −108.0% | −102.5% | −99.6% | 15.1% | −32.2% | −46.4% | −48.5% | −51.3% | −213.4% |
| Return on assets | −55.3% | −65.4% | −65.2% | −52.9% | 10.5% | −15.0% | −16.6% | −17.5% | −20.6% | −53.5% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |